We are live on ! Find out more
TENX icon

Tenax Therapeutics
TENX

11 hedge funds and large institutions have $1.04M invested in Tenax Therapeutics in 2017 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

10% more funds holding

Funds holding: 10 → 11 (+1)

0% more ownership

Funds ownership: 0% → 0% (+0%)

24% less capital invested

Capital invested by funds: $1.37M → $1.04M (-$327K)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $13K

Holders
11
Holders Change
+1
Holders Change %
+10%
% of All Funds
0.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
2
Reduced
1
Closed
1
Calls
–
Puts
$13K
Net Calls
-$13K
Net Calls Change
-$14K

Top Buyers

Rank Fund Capital Flow
1
FWP
FAS Wealth Partners
Kansas
+$594K
2
BBA
Baker Bros. Advisors
New York
+$104K
3
VF
Virtu Financial
New York
+$44.6K
4
Citadel Advisors
Citadel Advisors
Florida
+$29.7K
5
TSS
Two Sigma Securities
New York
+$14.9K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$223K
2
DADC
D.A. Davidson & Co
Montana
-$12K
3
Group One Trading
Group One Trading
Illinois
-$10K
4
TRCT
Tower Research Capital (TRC)
New York
-$10K
5
Creative Planning
Creative Planning
Kansas
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
FWP
1
FAS Wealth Partners
Kansas
$466K +$594K +40 New
Vanguard Group
2
Vanguard Group
Pennsylvania
$193K -$223K -15 -47%
BBA
3
Baker Bros. Advisors
New York
$126K +$104K +7 +175%
Millennium Management
4
Millennium Management
New York
$58K – – –
Bank of New York Mellon
5
Bank of New York Mellon
New York
$45K – – –
VF
6
Virtu Financial
New York
$37K +$44.6K +3 New
Geode Capital Management
7
Geode Capital Management
Massachusetts
$31K – – –
Citadel Advisors
8
Citadel Advisors
Florida
$30K +$29.7K +2 +200%
Northern Trust
9
Northern Trust
Illinois
$18K – – –
Verition Fund Management
10
Verition Fund Management
Connecticut
$12K – – –
TSS
11
Two Sigma Securities
New York
$8K +$14.9K +1 New
UBS Group
12
UBS Group
Switzerland
$6K – – –
BlackRock
13
BlackRock
New York
$5K – – –
CCMINC
14
Cardinal Capital Management Inc (North Carolina)
North Carolina
$3K – – –
Morgan Stanley
15
Morgan Stanley
New York
$2K – – –
DADC
16
D.A. Davidson & Co
Montana
– -$12K -1 Closed
Creative Planning
17
Creative Planning
Kansas
– -$1K – –
Group One Trading
18
Group One Trading
Illinois
– -$10K – –
TRCT
19
Tower Research Capital (TRC)
New York
– -$10K – –

TENX Hedge Fund Activity: Q3 2017 in Review

11 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Tenax Therapeutics (TENX) for Q3 2017, worth a combined $1.04M — down 24% from $1.37M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new TENX positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 1 trimmed.

The largest buyer was FAS Wealth Partners, opening a new position worth an estimated $594K. The largest seller was Vanguard Group, cutting an estimated $223K.

  • 11 institutional investors held Tenax Therapeutics (TENX) as of Q3 2017, up from 10 in Q2 2017.
  • Funds reported $1.04M of Tenax Therapeutics stock for Q3 2017, down 24% quarter-over-quarter.
  • 3 funds opened new Tenax Therapeutics positions in Q3 2017 and 1 closed out, a net change of +2 holders.
  • The largest Tenax Therapeutics buyer in Q3 2017 was FAS Wealth Partners, an estimated $594K added.
  • The largest Tenax Therapeutics seller in Q3 2017 was Vanguard Group, an estimated $223K sold.

Based on aggregated 13F filings for Q3 2017.